Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker

被引：0
作者：
Yumei Tang
Ye Lei
Peng Gao
Junting Jia
Huijun Du
Qitong Wang
Zhixin Yan
Chen Zhang
Guojun Liang
Yanfeng Wang
Weijun Ma
Nianzeng Xing
Le Cheng
Laifeng Ren
机构：
[1] Dali University,School of Basic Medical Sciences
[2] Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,Department of Immunology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital
[3] Shanxi Keda Research Institute,Department of Urology
[4] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Urology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital
[5] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Pharmacy, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital
[6] Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,Department of Cardiology
[7] BGI-Shenzhen,undefined
[8] Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,undefined
[9] the Fourth Affiliated Hospital of Harbin Medical University,undefined
[10] Shanxi Beike Biotechnology Co.,undefined
[11] Ltd,undefined
[12] BGI-Yunnan,undefined
来源：
BMC Cancer | / 23卷
关键词：
Cancers; Biomarker; Immune infiltration; Immunotherapy; Genomic instability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 200 条
  • [1] Siegel RL(2022)Cancer statistics, 2022 CA Cancer J Clin 72 7-33
  • [2] Miller KD(2021)Hallmarks of response, resistance, and toxicity to immune checkpoint blockade Cell 184 5309-37
  • [3] Fuchs HE(2018)Cancer immunotherapy using checkpoint blockade Science (New York, NY) 359 1350-5
  • [4] Jemal A(2022)Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment Nat Rev Drug Discov 21 440-462
  • [5] Morad G(2020)The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy Nat Rev Cancer 20 662-680
  • [6] Helmink BA(2017)Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet 389 255-265
  • [7] Sharma P(2019)Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade Clin Cancer Res 25 7024-7034
  • [8] Wargo JA(2020)CRL4(Cdt2): Coupling Genome Stability to Ubiquitination Trends Cell Biol 30 290-302
  • [9] Ribas A(2013)CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration Mol Cell 49 1147-1158
  • [10] Wolchok JD(2006)A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1 Mol Cell 23 709-721
12345678910